arXiv:2509. 23426v3 Announce Type: replace Abstract: AI scientists are emerging computational systems that serve as collaborative partners in discovery.
arXiv:2607. 16845v1 Announce Type: new Abstract: Scientists at European XFEL conduct experiments that generate very large and complex datasets.
arXiv:2604. 00137v2 Announce Type: replace Abstract: Tool-integrated LLMs retrieve information, perform computations, and take real-world actions, but their reliability depends on both tool-use accuracy and intrinsic tool accuracy, including tool correctness, stability, and safety.
arXiv:2607. 16038v1 Announce Type: new Abstract: Scientific work increasingly spans heterogeneous artifacts -- papers, code, datasets, scientific file formats, model outputs, figures, manuscripts, and team decisions -- yet general-purpose AI assistants rarely preserve these objects as a coherent, auditable research state.
arXiv:2606. 12736v1 Announce Type: new Abstract: AI agents are increasingly being developed to accelerate scientific discovery, yet their practical capabilities in real research settings remain poorly understood.
The paper introduces ScientistTwo, a fully autonomous multi‑agent framework that takes a scientific problem, establishes baselines, generates hypotheses, and coordinates specialized agents to conduct an end‑to‑end discovery cycle without human intervention. It rigorously tests and refines its methods through automated experiments, ablation studies, and a closed‑loop peer‑review engine. Benchmarking against top conferences (ICLR, ICML, NeurIPS) shows that ScientistTwo produces expert‑level, publishable papers and codebases that outperform human state‑of‑the‑art models and receive higher review ratings under automated AI review.
ClinAgent is a conversational system that uses a ReAct-based LLM agent to retrieve and synthesize clinical trial information from multiple sources such as ClinicalTrials.gov, PubMed, and a local dataset. The agent iteratively reasons over user queries, selects appropriate tools, and refines its actions to provide grounded, up-to-date responses in natural language across multi-turn interactions. Evaluation across three phases shows that DeepSeek (thinking mode) excels in planning quality while Gemini 3.0 Flash delivers the highest overall performance and expert ratings, demonstrating the promise of agentic AI for improving clinical trial data access.
arXiv:2607. 02703v1 Announce Type: cross Abstract: In this paper, we describe LLMoxie, an institutional AI platform whose three-tiered architecture supports multi-cloud and on-premise inference, a LiteLLM/MLflow control plane for authentication, budgeting, PII masking, and observability, and an application augmentation layer for AI coding agents.
OSWorld-Science is a benchmark and evaluation environment for computer-using agents that use visual language models (VLMs) to perform scientific software tasks. It includes 12 VLMs and 146 high-quality tasks across domains such as molecular drawing, pathology image analysis, statistical computing, and physical simulation, with artifact-based evaluation and a harness that logs interactions and supports model comparison. The benchmark was developed through expert proposals and iterative human–AI co‑design, and results show that current VLMs still struggle with key scientific questions, offering insights into factors like language, reasoning, and context length.
arXiv:2603. 01421v3 Announce Type: replace Abstract: While large language models accelerate scientific discovery, existing agents face severe limitations in adaptability, domain generalization, and multimodal scalability, often struggling to autonomously process raw, domain-specific experimental data.
arXiv:2606. 15497v1 Announce Type: new Abstract: The automation of science is a long-standing ambition in the field of AI.
arXiv:2606. 31229v1 Announce Type: new Abstract: Ideation plays a pivotal role in scientific discovery.
arXiv:2602. 02905v2 Announce Type: replace Abstract: Autonomous agents powered by large language models (LLMs) promise to accelerate scientific discovery end-to-end, but rigorously evaluating their capacity for verifiable discovery remains a central challenge.